2024
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
Kondo T, Mogensen U, Talebi A, Gasparyan S, Campbell R, Docherty K, de Boer R, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. Journal Of The American College Of Cardiology 2024, 83: 1973-1986. PMID: 38537918, DOI: 10.1016/j.jacc.2024.03.385.Peer-Reviewed Original ResearchConceptsDAPA-HFLeft ventricular ejection fractionNYHA functional class IIEfficacy of dapagliflozinFunctional class IIIV heart failureVentricular ejection fractionEffects of dapagliflozinHeart failure hospitalizationDAPA-HF trialWell-beingFollow-up daysBetween-treatment differencesDapagliflozin groupPlacebo groupTime-to-first-event analysisEjection fractionFailure hospitalizationPatient well-beingHeart failureCardiovascular deathDapagliflozinRecurrent hospitalizationsClass IIPlacebo
2023
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER
Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseModerate chronic obstructive pulmonary diseaseCOPD statusSafety of dapagliflozinObstructive pulmonary diseaseHeart failurePulmonary diseasePrimary outcomeEjection fractionWorse outcomesKansas City Cardiomyopathy Questionnaire scoreBenefit of dapagliflozinPre-specified analysisSevere pulmonary diseaseCardiovascular deathCause hospitalizationPrimary endpointTreatment discontinuationAdverse eventsClinical eventsQuestionnaire scoresPlaceboDapagliflozinPatientsKnown historyDapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireActivity limitation scoresEffect of dapagliflozinLimitation scoresSocial activity limitationsHeart failureActivity limitationsDAPA-HF trialReduced ejection fractionProportion of patientsActivity limitation domainLimitation domainEjection fractionPhysical functionChronic diseasesDapagliflozinPatientsHealth statusPlaceboMixed-effects modelsMonthsBaselineComplete dataScoresSocial limitations
2021
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseNAFLD fibrosis scoreCardiorenal outcomesFibrosis riskEMPA-REG OUTCOMELiver fat contentRisk of steatosisEffect of empagliflozinFatty liver diseaseType 2 diabetesCause deathDaily empagliflozinSteatosis indexHeart failureFibrosis scoreLiver diseaseCox regressionCardiovascular diseaseHigh riskEmpagliflozinPlaceboSteatosisRisk categoriesBaselineMeasures analysis
2020
Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF
Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.Peer-Reviewed Original ResearchMineralocorticoid receptor antagonistsRisk of hyperkalaemiaReduced ejection fractionSevere hyperkalaemiaMild hyperkalaemiaDAPA-HFHazard ratioEjection fractionHeart failureMRA useSodium-glucose cotransporter 2 inhibitor dapagliflozinDAPA-HF studyHeart Failure TrialCox regression analysisLife-saving therapyInhibitor dapagliflozinFailure TrialAdverse outcomesReceptor antagonistHyperkalaemiaPatientsDapagliflozinTreatment assignmentHFrEFPlacebo30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.Peer-Reviewed Original ResearchInsulin-naïve patientsInsulin useBackground glucose-lowering therapyEMPA-REG OUTCOMEInsulin dose increasesInsulin-treated patientsGlucose-lowering therapyEmpagliflozin 10T2D durationInsulin doseT2D diagnosisInsulin needsPlaceboPatientsWeight gainKey covariatesDose increaseInsulinTreatment effectsNew initiationHypoglycemiaT2DTherapyYrDiagnosis